» Articles » PMID: 35791440

Determination of Time in Range Associated With HbA1c ≤7% in a Prospective Cohort of Patients With Type 1 Diabetes Using Continuous Glucose Monitoring for Three Months

Overview
Specialty Endocrinology
Date 2022 Jul 6
PMID 35791440
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Finding a goal of time in range (%TIR) that defines good glycemic control is necessary. Previous retrospective studies suggest good concordance between HbA1c ≤7% with a TIR >70%; however, the studies that included the largest number of patients used blood glucose measurement data with a follow-up time of less than 90 days. This study defined the TIR value that best discriminates HbA1c ≤7%.

Methods: We performed a prospective study of diagnostic tests based on a cohort of patients with type 1 diabetes (T1D) treated with a hybrid closed loop (HCL) followed for three months. The ability of %TIR to distinguish patients with HbA1c ≤7% was evaluated through receiver operating characteristic curve analysis. We determined the %TIR cutoff point with the best operating characteristics.

Results: A total of 118 patients were included (58.1% women, 47% overweight or obese, and 33% with high glycemic variability). A moderate negative correlation ( = -.54, < .001) was found between %TIR and HbA1c. The discrimination ability was moderate, with an area under the curve of 0.7485 (95% confidence interval = 0.6608-0.8363). The cutoff point that best predicted HbA1c ≤7% was %TIR ≥75.5 (sensitivity 70%, specificity 67%). The findings were similar among those with a coefficient of variation (CV%) ≥36%.

Conclusions: Our data suggest that the %TIR adequately identifies patients with HbA1c ≤7%. A target of TIR ≥75%, rather than the currently recommended TIR ≥70%, may be a more suitable value for optimal glycemic control.

Citing Articles

Construction of a 3-year risk prediction model for developing diabetes in patients with pre-diabetes.

Yang J, Liu D, Du Q, Zhu J, Lu L, Wu Z Front Endocrinol (Lausanne). 2024; 15:1410502.

PMID: 38938520 PMC: 11208327. DOI: 10.3389/fendo.2024.1410502.

References
1.
Advani A . Positioning time in range in diabetes management. Diabetologia. 2019; 63(2):242-252. DOI: 10.1007/s00125-019-05027-0. View

2.
Beck R, Bergenstal R, Riddlesworth T, Kollman C, Li Z, Brown A . Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2018; 42(3):400-405. PMC: 6905478. DOI: 10.2337/dc18-1444. View

3.
Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

4.
Lachin J, White N, Hainsworth D, Sun W, Cleary P, Nathan D . Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2014; 64(2):631-42. PMC: 4303965. DOI: 10.2337/db14-0930. View

5.
Beck R, Bergenstal R, Cheng P, Kollman C, Carlson A, Johnson M . The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. J Diabetes Sci Technol. 2019; 13(4):614-626. PMC: 6610606. DOI: 10.1177/1932296818822496. View